235 related articles for article (PubMed ID: 31179490)
1. Laminin-111 protein therapy enhances muscle regeneration and repair in the GRMD dog model of Duchenne muscular dystrophy.
Barraza-Flores P; Fontelonga TM; Wuebbles RD; Hermann HJ; Nunes AM; Kornegay JN; Burkin DJ
Hum Mol Genet; 2019 Aug; 28(16):2686-2695. PubMed ID: 31179490
[TBL] [Abstract][Full Text] [Related]
2. Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever Muscular Dystrophy dog model for Duchenne Muscular Dystrophy.
Terrill JR; Duong MN; Turner R; Le Guiner C; Boyatzis A; Kettle AJ; Grounds MD; Arthur PG
Redox Biol; 2016 Oct; 9():276-286. PubMed ID: 27611888
[TBL] [Abstract][Full Text] [Related]
3. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
[TBL] [Abstract][Full Text] [Related]
4. Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.
Robriquet F; Babarit C; Larcher T; Dubreil L; Ledevin M; Goubin H; Rouger K; Guével L
BMC Musculoskelet Disord; 2016 May; 17():209. PubMed ID: 27170302
[TBL] [Abstract][Full Text] [Related]
5. The golden retriever model of Duchenne muscular dystrophy.
Kornegay JN
Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
[TBL] [Abstract][Full Text] [Related]
6. Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy.
Wuebbles RD; Sarathy A; Kornegay JN; Burkin DJ
Dis Model Mech; 2013 Sep; 6(5):1175-84. PubMed ID: 23846963
[TBL] [Abstract][Full Text] [Related]
7. Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.
Kornegay JN; Bogan JR; Bogan DJ; Childers MK; Li J; Nghiem P; Detwiler DA; Larsen CA; Grange RW; Bhavaraju-Sanka RK; Tou S; Keene BP; Howard JF; Wang J; Fan Z; Schatzberg SJ; Styner MA; Flanigan KM; Xiao X; Hoffman EP
Mamm Genome; 2012 Feb; 23(1-2):85-108. PubMed ID: 22218699
[TBL] [Abstract][Full Text] [Related]
8. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.
Banks GB; Chamberlain JS
Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide association study to identify potential genetic modifiers in a canine model for Duchenne muscular dystrophy.
Brinkmeyer-Langford C; Balog-Alvarez C; Cai JJ; Davis BW; Kornegay JN
BMC Genomics; 2016 Aug; 17(1):665. PubMed ID: 27549615
[TBL] [Abstract][Full Text] [Related]
10. Translating golden retriever muscular dystrophy microarray findings to novel biomarkers for cardiac/skeletal muscle function in Duchenne muscular dystrophy.
Galindo CL; Soslow JH; Brinkmeyer-Langford CL; Gupte M; Smith HM; Sengsayadeth S; Sawyer DB; Benson DW; Kornegay JN; Markham LW
Pediatr Res; 2016 Apr; 79(4):629-36. PubMed ID: 26672735
[TBL] [Abstract][Full Text] [Related]
11. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
12. Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.
Brinkmeyer-Langford C; Chu C; Balog-Alvarez C; Yu X; Cai JJ; Nabity M; Kornegay JN
PLoS One; 2018; 13(3):e0194485. PubMed ID: 29554127
[TBL] [Abstract][Full Text] [Related]
13. Human adipose-derived mesenchymal stromal cells injected systemically into GRMD dogs without immunosuppression are able to reach the host muscle and express human dystrophin.
Vieira NM; Valadares M; Zucconi E; Secco M; Bueno CR; Brandalise V; Assoni A; Gomes J; Landini V; Andrade T; Caetano HV; Vainzof M; Zatz M
Cell Transplant; 2012; 21(7):1407-17. PubMed ID: 23168016
[TBL] [Abstract][Full Text] [Related]
14. Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy.
Barthélémy I; Pinto-Mariz F; Yada E; Desquilbet L; Savino W; Silva-Barbosa SD; Faussat AM; Mouly V; Voit T; Blot S; Butler-Browne G
Dis Model Mech; 2014 Nov; 7(11):1253-61. PubMed ID: 25261568
[TBL] [Abstract][Full Text] [Related]
15. Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength.
Martin PT; Zygmunt DA; Ashbrook A; Hamilton S; Packer D; Birch SM; Bettis AK; Balog-Alvarez CJ; Guo LJ; Nghiem PP; Kornegay JN
PLoS One; 2021; 16(3):e0248721. PubMed ID: 33770101
[TBL] [Abstract][Full Text] [Related]
16. Glucose Metabolism as a Pre-clinical Biomarker for the Golden Retriever Model of Duchenne Muscular Dystrophy.
Schneider SM; Sridhar V; Bettis AK; Heath-Barnett H; Balog-Alvarez CJ; Guo LJ; Johnson R; Jaques S; Vitha S; Glowcwski AC; Kornegay JN; Nghiem PP
Mol Imaging Biol; 2018 Oct; 20(5):780-788. PubMed ID: 29508262
[TBL] [Abstract][Full Text] [Related]
17. Natural History of Cardiomyopathy in Adult Dogs With Golden Retriever Muscular Dystrophy.
Guo LJ; Soslow JH; Bettis AK; Nghiem PP; Cummings KJ; Lenox MW; Miller MW; Kornegay JN; Spurney CF
J Am Heart Assoc; 2019 Aug; 8(16):e012443. PubMed ID: 31411085
[TBL] [Abstract][Full Text] [Related]
18. Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.
Goudenege S; Lamarre Y; Dumont N; Rousseau J; Frenette J; Skuk D; Tremblay JP
Mol Ther; 2010 Dec; 18(12):2155-63. PubMed ID: 20683444
[TBL] [Abstract][Full Text] [Related]
19. A computerized MRI biomarker quantification scheme for a canine model of Duchenne muscular dystrophy.
Wang J; Fan Z; Vandenborne K; Walter G; Shiloh-Malawsky Y; An H; Kornegay JN; Styner MA
Int J Comput Assist Radiol Surg; 2013 Sep; 8(5):763-74. PubMed ID: 23299128
[TBL] [Abstract][Full Text] [Related]
20. Use of the six-minute walk test to characterize golden retriever muscular dystrophy.
Acosta AR; Van Wie E; Stoughton WB; Bettis AK; Barnett HH; LaBrie NR; Balog-Alvarez CJ; Nghiem PP; Cummings KJ; Kornegay JN
Neuromuscul Disord; 2016 Dec; 26(12):865-872. PubMed ID: 27818009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
